FDA approves Roche's breast cancer pill Wilserdly in the U.S.
FROM THE WIRE · SEEKINGALPHA.COM
[Roche Diagnostics campus facade in Silicon Valley] Michael Vi/iStock Editorial via Getty Images Roche (RHHBF [https://seekingalpha.com/symbol/RHHBF]) has announced that the FDA approved its new breast cancer therapy Wilserdly (giredestrant), marking the first of two U.S.…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA new oral therapy approved in the U.S. can strengthen Roche's commercial outlook in oncology.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA approved Wilserdly (giredestrant) for ER-positive, HER2-negative, ESR1-mutated breast cancer.
- 02It will be indicated with everolimus for adults whose disease returned or progressed after endocrine therapy.
- 03Roche plans to launch the drug in the U.S. almost immediately at a list price of $22,500 per month.
- 04It is the first of two U.S. regulatory decisions expected this year for the oral therapy.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Roche Holding AG60.95 USDMarket closedtoday +1.08%Positive Roche Holding AG505.05 USDMarket closedtoday +5.23%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets